{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:02:56Z","timestamp":1793880176695,"version":"4.7.0"},"reference-count":126,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolism"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.diabet.2020.01.002","type":"journal-article","created":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T05:26:56Z","timestamp":1580362016000},"page":"186-196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials"],"prefix":"10.1016","volume":"46","author":[{"given":"A.J.","family":"Scheen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2020.01.002_bib0630","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/dom.13047","article-title":"Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"20","author":"Wang","year":"2018","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.diabet.2020.01.002_bib0635","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.diabet.2018.01.017","article-title":"Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"44","author":"Mishriky","year":"2018","journal-title":"Diab Metab"},{"key":"10.1016\/j.diabet.2020.01.002_bib0640","first-page":"478","article-title":"Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus with inadequate glycemic control on metformin: a meta-analysis","volume":"63","author":"Jingfan","year":"2019","journal-title":"Arch Endocrinol Metab"},{"key":"10.1016\/j.diabet.2020.01.002_bib0645","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/dom.12128","article-title":"Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence","volume":"16","author":"Liu","year":"2014","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.diabet.2020.01.002_bib0650","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.2337\/db14-0052","article-title":"Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors","volume":"63","author":"Omar","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2020.01.002_bib0655","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","article-title":"Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus","volume":"75","author":"Scheen","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.diabet.2020.01.002_bib0660","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrneph.2016.170","article-title":"Renal, metabolic and cardiovascular considerations of SGLT2 inhibition","volume":"13","author":"DeFronzo","year":"2017","journal-title":"Nature Rev Nephrol"},{"key":"10.1016\/j.diabet.2020.01.002_bib0665","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1161\/CIRCRESAHA.117.311588","article-title":"Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors","volume":"122","author":"Scheen","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.diabet.2020.01.002_bib0670","article-title":"Implications of the recent CVOTs in Type 2 diabetes: impact on guidelines: the endocrinologist point of view","author":"Scheen","year":"2019","journal-title":"Diab Res Clin Pract"},{"key":"10.1016\/j.diabet.2020.01.002_bib0675","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1007\/s00125-018-4729-5","article-title":"Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"61","author":"Davies","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2020.01.002_bib0680","doi-asserted-by":"crossref","first-page":"e0125879","DOI":"10.1371\/journal.pone.0125879","article-title":"Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis","volume":"10","author":"Mearns","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.diabet.2020.01.002_bib0685","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S2213-8587(13)70095-0","article-title":"SGLT2 versus DPP4 inhibitors for type 2 diabetes","volume":"1","author":"Scheen","year":"2013","journal-title":"Lancet Diab Endocrinol"},{"key":"10.1016\/j.diabet.2020.01.002_bib0690","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1016\/j.clinthera.2017.10.016","article-title":"Choosing dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter-2 inhibitors, or both, as add-ons to metformin: patient baseline characteristics are crucial","volume":"39","author":"Goldenberg","year":"2017","journal-title":"Clin Ther"},{"key":"10.1016\/j.diabet.2020.01.002_bib0695","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1464-5491.2010.02941.x","article-title":"Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials","volume":"27","author":"DeFronzo","year":"2010","journal-title":"Diab Med"},{"key":"10.1016\/j.diabet.2020.01.002_bib0700","doi-asserted-by":"crossref","first-page":"906","DOI":"10.4158\/EP.17.6.906","article-title":"Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program","volume":"17","author":"Henry","year":"2011","journal-title":"Endocr Pract"},{"key":"10.1016\/j.diabet.2020.01.002_bib0705","doi-asserted-by":"crossref","first-page":"e00016","DOI":"10.1002\/edm2.16","article-title":"Slope of change in HbA1c from baseline with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes","volume":"1","author":"DeFronzo","year":"2018","journal-title":"Endocrinol Diab Metab"},{"key":"10.1016\/j.diabet.2020.01.002_bib0710","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2213-8587(13)70084-6","article-title":"Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"1","author":"Roden","year":"2013","journal-title":"Lancet Diab Endocrinol"},{"key":"10.1016\/j.diabet.2020.01.002_bib0715","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabet.2020.01.002_bib0720","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Bailey","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2020.01.002_bib0725","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.2337\/dc11-0606","article-title":"Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial","volume":"34","author":"Nauck","year":"2011","journal-title":"Diab Care"},{"key":"10.1016\/j.diabet.2020.01.002_bib0730","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2020.01.002_bib0735","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.2337\/dc11-1926","article-title":"Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes","volume":"35","author":"Rosenstock","year":"2012","journal-title":"Diab Care"},{"key":"10.1016\/j.diabet.2020.01.002_bib0740","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","article-title":"Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial","volume":"382","author":"Cefalu","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2020.01.002_bib0745","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1741-7015-11-43","article-title":"Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial","volume":"11","author":"Bailey","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.diabet.2020.01.002_bib0750","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/dom.12038","article-title":"Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study","volume":"15","author":"Wilding","year":"2013","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.diabet.2020.01.002_bib0755","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/dom.12185","article-title":"Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia","volume":"15","author":"Rosenstock","year":"2013","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.diabet.2020.01.002_bib0760","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1007\/s00125-013-3039-1","article-title":"Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial","volume":"56","author":"Lavalle-Gonzalez","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2020.01.002_bib0765","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(14)70120-2","article-title":"Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial","volume":"2","author":"Ridderstrale","year":"2014","journal-title":"Lancet Diab Endocrinol"},{"key":"10.1016\/j.diabet.2020.01.002_bib0770","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.2337\/dc13-2105","article-title":"Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial","volume":"37","author":"Haring","year":"2014","journal-title":"Diab Care"},{"key":"10.1016\/j.diabet.2020.01.002_bib0775","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/dom.12331","article-title":"Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study","volume":"17","author":"Kashiwagi","year":"2015","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.diabet.2020.01.002_bib0780","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/dom.12385","article-title":"Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea","volume":"17","author":"Ji","year":"2015","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.diabet.2020.01.002_bib0785","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/dom.12387","article-title":"Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial","volume":"17","author":"Schumm-Draeger","year":"2015","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.diabet.2020.01.002_bib0790","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/dom.12469","article-title":"Efficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin: a 16-week, randomized, placebo-controlled trial","volume":"17","author":"Ross","year":"2015","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.diabet.2020.01.002_bib0795","doi-asserted-by":"crossref","first-page":"376","DOI":"10.2337\/dc14-1142","article-title":"Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin","volume":"38","author":"Rosenstock","year":"2015","journal-title":"Diab Care"},{"key":"10.1016\/j.diabet.2020.01.002_bib0800","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2337\/dc14-0890","article-title":"Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy","volume":"38","author":"Rosenstock","year":"2015","journal-title":"Diab Care"},{"key":"10.1016\/j.diabet.2020.01.002_bib0805","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2337\/dc14-2364","article-title":"Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin","volume":"38","author":"DeFronzo","year":"2015","journal-title":"Diab Care"},{"key":"10.1016\/j.diabet.2020.01.002_bib0810","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/dom.12460","article-title":"Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin","volume":"17","author":"Amin","year":"2015","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.diabet.2020.01.002_bib0815","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/1753-0407.12357","article-title":"Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: a randomized controlled trial","volume":"8","author":"Yang","year":"2016","journal-title":"J Diab"},{"key":"10.1016\/j.diabet.2020.01.002_bib0820","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/jdi.12422","article-title":"Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: results of a phase 3 randomized, placebo-controlled, double-blind, multicenter trial","volume":"7","author":"Lu","year":"2016","journal-title":"J Diab Investig"},{"key":"10.1016\/j.diabet.2020.01.002_bib0825","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S2213-8587(16)30267-4","volume":"4","author":"Frias","year":"2016","journal-title":"Lancet Diab Endocrinol"},{"key":"10.1016\/j.diabet.2020.01.002_bib0830","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/dom.13103","article-title":"Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET)","volume":"20","author":"Rosenstock","year":"2018","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.diabet.2020.01.002_bib0835","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.diabres.2018.10.018","article-title":"A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus","volume":"146","author":"Shestakova","year":"2018","journal-title":"Diab Res Clin Pract"},{"key":"10.1016\/j.diabet.2020.01.002_bib0840","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/dom.13194","article-title":"Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: the VERTIS FACTORIAL randomized trial","volume":"20","author":"Pratley","year":"2018","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.diabet.2020.01.002_bib0845","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1111\/dom.13437","article-title":"Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes","volume":"20","author":"Muller-Wieland","year":"2018","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.diabet.2020.01.002_bib0850","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s13300-017-0354-4","article-title":"Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: the VERTIS SU randomized study","volume":"9","author":"Hollander","year":"2018","journal-title":"Diab Ther"},{"key":"10.1016\/j.diabet.2020.01.002_bib0855","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S2213-8587(19)30311-0","article-title":"Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, randomised, controlled trial","volume":"7","author":"Lingvay","year":"2019","journal-title":"Lancet Diab Endocrinol"},{"key":"10.1016\/j.diabet.2020.01.002_bib0860","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.2337\/dc19-0883","article-title":"Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial","volume":"42","author":"Rodbard","year":"2019","journal-title":"Diab Care"},{"key":"10.1016\/j.diabet.2020.01.002_bib0865","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.2337\/diacare.27.12.2874","article-title":"Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes","volume":"27","author":"Ahren","year":"2004","journal-title":"Diab Care"},{"key":"10.1016\/j.diabet.2020.01.002_bib0870","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.2337\/dc06-0706","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone","volume":"29","author":"Charbonnel","year":"2006","journal-title":"Diab Care"},{"key":"10.1016\/j.diabet.2020.01.002_bib0875","doi-asserted-by":"crossref","first-page":"890","DOI":"10.2337\/dc06-1732","article-title":"Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin","volume":"30","author":"Bosi","year":"2007","journal-title":"Diab Care"},{"key":"10.1016\/j.diabet.2020.01.002_bib0880","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.2337\/dc07-0627","article-title":"Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes","volume":"30","author":"Goldstein","year":"2007","journal-title":"Diab Care"},{"key":"10.1016\/j.diabet.2020.01.002_bib0885","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1463-1326.2006.00704.x","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial","volume":"9","author":"Nauck","year":"2007","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.diabet.2020.01.002_bib0890","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.2337\/dc08-1035","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study","volume":"31","author":"DeFronzo","year":"2008","journal-title":"Diab Care"},{"key":"10.1016\/j.diabet.2020.01.002_bib0895","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/j.1463-1326.2007.00839.x","article-title":"Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes","volume":"10","author":"Scott","year":"2008","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.diabet.2020.01.002_bib0900","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1185\/030079908X260925","article-title":"Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes","volume":"24","author":"Raz","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.diabet.2020.01.002_bib0905","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1055\/s-0028-1104604","article-title":"Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy","volume":"41","author":"Goodman","year":"2009","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.diabet.2020.01.002_bib0910","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1742-1241.2008.01933.x","article-title":"Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study","volume":"63","author":"Nauck","year":"2009","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.diabet.2020.01.002_bib0915","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.2337\/dc08-1984","article-title":"The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone","volume":"32","author":"DeFronzo","year":"2009","journal-title":"Diab Care"},{"key":"10.1016\/j.diabet.2020.01.002_bib0920","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1463-1326.2008.00994.x","article-title":"Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy","volume":"11","author":"Ferrannini","year":"2009","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.diabet.2020.01.002_bib0925","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/j.1463-1326.2009.01080.x","article-title":"Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial \u2013 A primary care, type 2 diabetes study","volume":"11","author":"Blonde","year":"2009","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.diabet.2020.01.002_bib0930","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/j.1463-1326.2008.01023.x","article-title":"Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin","volume":"11","author":"Bolli","year":"2009","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.diabet.2020.01.002_bib0935","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1464-5491.2010.02938.x","article-title":"A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study","volume":"27","author":"Filozov","year":"2010","journal-title":"Diab Med"},{"key":"10.1016\/j.diabet.2020.01.002_bib0940","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/j.1464-5491.2010.03131.x","article-title":"Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes","volume":"27","author":"Forst","year":"2010","journal-title":"Diab Med"},{"key":"10.1016\/j.diabet.2020.01.002_bib0945","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0140-6736(10)60590-9","article-title":"Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial","volume":"376","author":"Bergenstal","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2020.01.002_bib0950","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4158\/EP09146.OR","article-title":"Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy","volume":"16","author":"Rigby","year":"2010","journal-title":"Endocr Pract"},{"key":"10.1016\/j.diabet.2020.01.002_bib0955","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/dmrr.1114","article-title":"Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus","volume":"26","author":"Scheen","year":"2010","journal-title":"Diab Metab Res Rev"},{"key":"10.1016\/j.diabet.2020.01.002_bib0960","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1111\/j.1742-1241.2010.02510.x","article-title":"Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial","volume":"64","author":"Goke","year":"2010","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.diabet.2020.01.002_bib0965","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(10)60307-8","article-title":"Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial","volume":"375","author":"Pratley","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2020.01.002_bib0970","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4239\/wjd.v1.i1.19","article-title":"Effect of vildagliptin as add-on therapy to a low-dose metformin","volume":"1","author":"Filozof","year":"2010","journal-title":"World J Diab"},{"key":"10.1016\/j.diabet.2020.01.002_bib0975","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1463-1326.2010.01326.x","article-title":"Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study","volume":"13","author":"Taskinen","year":"2011","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.diabet.2020.01.002_bib0980","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.diabres.2011.07.035","article-title":"Efficacy and safety of saxagliptin added to metformin in Asian patients with type 2 diabetes mellitus: a randomized controlled trial","volume":"94","author":"Yang","year":"2011","journal-title":"Diab Res Clin Pract"},{"key":"10.1016\/j.diabet.2020.01.002_bib0985","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1463-1326.2010.01334.x","article-title":"Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial","volume":"13","author":"Arechavaleta","year":"2011","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.diabet.2020.01.002_bib0990","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s13300-012-0013-8","article-title":"Efficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-emerge 4 trial)","volume":"3","author":"Bergenstal","year":"2012","journal-title":"Diab Ther"},{"key":"10.1016\/j.diabet.2020.01.002_bib0995","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1463-1326.2012.01593.x","article-title":"Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus","volume":"14","author":"Pan","year":"2012","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.diabet.2020.01.002_bib1000","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1089\/dia.2011.0278","article-title":"Vildagliptin added to metformin on beta-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients","volume":"14","author":"Derosa","year":"2012","journal-title":"Diab Technol Ther"},{"key":"10.1016\/j.diabet.2020.01.002_bib1005","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1185\/03007995.2012.714360","article-title":"Efficacy and safety of linagliptin 2.5\u00a0mg twice daily versus 5\u00a0mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial","volume":"28","author":"Ross","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.diabet.2020.01.002_bib1010","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(12)60691-6","article-title":"2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial","volume":"380","author":"Gallwitz","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2020.01.002_bib1015","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1753-0407.2012.00213.x","article-title":"The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes","volume":"4","author":"Yang","year":"2012","journal-title":"J Diab"},{"key":"10.1016\/j.diabet.2020.01.002_bib1020","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/j.1463-1326.2012.01620.x","article-title":"Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study","volume":"14","author":"Seino","year":"2012","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.diabet.2020.01.002_bib1025","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1016\/S0140-6736(12)60439-5","article-title":"Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial","volume":"379","author":"Aschner","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2020.01.002_bib1030","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1185\/03007995.2012.735646","article-title":"Effects of saxagliptin added to sub-maximal doses of metformin compared with uptitration of metformin in type 2 diabetes: the PROMPT study","volume":"28","author":"Hermans","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.diabet.2020.01.002_bib1035","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/dom.12060","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone","volume":"15","author":"Rhee","year":"2013","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.diabet.2020.01.002_bib1040","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s00125-013-2905-1","volume":"56","author":"Charbonnel","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2020.01.002_bib1045","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s13300-014-0059-x","article-title":"Efficacy and safety of vildagliptin as add-on to metformin in Japanese patients with type 2 diabetes mellitus","volume":"5","author":"Odawara","year":"2014","journal-title":"Diab Ther"},{"key":"10.1016\/j.diabet.2020.01.002_bib1050","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.2337\/dc13-2761","article-title":"Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5)","volume":"37","author":"Nauck","year":"2014","journal-title":"Diab Care"},{"key":"10.1016\/j.diabet.2020.01.002_bib1055","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1472-6823-14-17","article-title":"A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy","volume":"14","author":"White","year":"2014","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.diabet.2020.01.002_bib1060","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/2042018815595584","article-title":"Patient preference and tolerability of a DPP-4 inhibitor versus a GLP-1 analog in patients with type 2 diabetes mellitus inadequately controlled with metformin: a 24-week, randomized, multicenter, crossover study","volume":"6","author":"Ludemann","year":"2015","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.diabet.2020.01.002_bib1065","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/dom.12461","article-title":"Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION)","volume":"17","author":"Schernthaner","year":"2015","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.diabet.2020.01.002_bib1070","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/dom.12424","article-title":"Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial","volume":"17","author":"Kim","year":"2015","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.diabet.2020.01.002_bib1075","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/1753-0407.12284","article-title":"Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled by metformin: a multinational 24-week, randomized clinical trial","volume":"8","author":"Wang","year":"2016","journal-title":"J Diab"},{"key":"10.1016\/j.diabet.2020.01.002_bib1080","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/dom.12667","article-title":"Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION)","volume":"18","author":"Ji","year":"2016","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.diabet.2020.01.002_bib1085","doi-asserted-by":"crossref","first-page":"230","DOI":"10.4093\/dmj.2016.40.3.230","article-title":"Comparison of vildagliptin and pioglitazone in Korean patients with type 2 diabetes inadequately controlled with metformin","volume":"40","author":"Kim","year":"2016","journal-title":"Diab Metab J"},{"key":"10.1016\/j.diabet.2020.01.002_bib1090","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/1753-0407.12425","article-title":"Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double-blind placebo-controlled Phase 3 study in mainland China, Taiwan, and Hong Kong","volume":"9","author":"Pan","year":"2017","journal-title":"J Diab"},{"key":"10.1016\/j.diabet.2020.01.002_bib1095","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/dom.12832","volume":"19","author":"Goldenberg","year":"2017","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.diabet.2020.01.002_bib1100","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/dom.12870","article-title":"Efficacy and safety of adding evogliptin versus sitagliptin for metformin-treated patients with type 2 diabetes: a 24-week randomized, controlled trial with open label extension","volume":"19","author":"Hong","year":"2017","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.diabet.2020.01.002_bib1105","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/dom.12908","article-title":"Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: the DURATION-NEO-2 randomized clinical study","volume":"19","author":"Gadde","year":"2017","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.diabet.2020.01.002_bib1110","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1111\/dom.12942","article-title":"Efficacy and safety of saxagliptin compared with acarbose in Chinese patients with type 2 diabetes mellitus uncontrolled on metformin monotherapy: results of a Phase IV open-label randomized controlled study (the SMART study)","volume":"19","author":"Du","year":"2017","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.diabet.2020.01.002_bib1115","doi-asserted-by":"crossref","first-page":"107860","DOI":"10.1016\/j.diabres.2019.107860","article-title":"Efficacy and safety of evogliptin versus sitagliptin as an add-on therapy in Indian patients with type 2 diabetes mellitus inadequately controlled with metformin: a 24-week randomized, double-blind, non-inferiority, EVOLUTION INDIA study","volume":"157","author":"Ajmani","year":"2019","journal-title":"Diab Res Clin Pract"},{"key":"10.1016\/j.diabet.2020.01.002_bib1120","article-title":"Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes","author":"Handelsman","year":"2018","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.diabet.2020.01.002_bib1125","doi-asserted-by":"crossref","first-page":"e009417","DOI":"10.1136\/bmjopen-2015-009417","article-title":"SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis","volume":"6","author":"Shyangdan","year":"2016","journal-title":"BMJ open"},{"key":"10.1016\/j.diabet.2020.01.002_bib1130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13300-014-0061-3","article-title":"Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison","volume":"5","author":"Craddy","year":"2014","journal-title":"Diab Ther"},{"key":"10.1016\/j.diabet.2020.01.002_bib1135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CM9.0000000000000012","article-title":"Treatment response between Asian and non-Asian patients with type 2 diabetes: is there any similarity or difference?","volume":"132","author":"Cai","year":"2019","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.diabet.2020.01.002_bib1140","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s00125-012-2827-3","article-title":"Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis","volume":"56","author":"Kim","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2020.01.002_bib1145","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/1753-0407.12196","article-title":"Efficacy of dipeptidyl-peptidase-4 inhibitors and impact on beta-cell function in Asian and Caucasian type 2 diabetes mellitus patients: a meta-analysis","volume":"7","author":"Cai","year":"2015","journal-title":"J Diab"},{"key":"10.1016\/j.diabet.2020.01.002_bib1150","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/jdi.12760","article-title":"No disparity of the efficacy and all-cause mortality between Asian and non-Asian type 2 diabetes patients with sodium-glucose cotransporter 2 inhibitors treatment: a meta-analysis","volume":"9","author":"Cai","year":"2018","journal-title":"J Diab Investig"},{"key":"10.1016\/j.diabet.2020.01.002_bib1155","doi-asserted-by":"crossref","first-page":"e0152428","DOI":"10.1371\/journal.pone.0152428","article-title":"Should studies of diabetes treatment stratification correct for baseline HbA1c?","volume":"11","author":"Jones","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.diabet.2020.01.002_bib1160","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s12020-013-0090-0","article-title":"Baseline glycemic parameters predict the hemoglobin A1c response to DPP-4 inhibitors: meta-regression analysis of 78 randomized controlled trials with 20,053 patients","volume":"46","author":"Esposito","year":"2014","journal-title":"Endocrine"},{"key":"10.1016\/j.diabet.2020.01.002_bib1165","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.diabet.2017.10.003","article-title":"Predictors of the response of HbA1c and body weight after SGLT2 inhibition","volume":"44","author":"Abe","year":"2018","journal-title":"Diab Metab"},{"key":"10.1016\/j.diabet.2020.01.002_bib1170","first-page":"4509603","article-title":"C-peptide levels predict the effectiveness of dipeptidyl peptidase-4 inhibitor therapy","volume":"2016","author":"Demir","year":"2016","journal-title":"J Diab Res"},{"key":"10.1016\/j.diabet.2020.01.002_bib1175","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4093\/dmj.2011.35.2.159","article-title":"Predictive clinical parameters for the therapeutic efficacy of sitagliptin in Korean type 2 diabetes mellitus","volume":"35","author":"Kim","year":"2011","journal-title":"Diab Metab J"},{"key":"10.1016\/j.diabet.2020.01.002_bib1180","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1365-2265.2011.04240.x","article-title":"Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study","volume":"77","author":"Lim","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.diabet.2020.01.002_bib1185","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2337\/diacare.26.3.881","article-title":"Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c)","volume":"26","author":"Monnier","year":"2003","journal-title":"Diab Care"},{"key":"10.1016\/j.diabet.2020.01.002_bib1190","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/bcp.13807","article-title":"Efficacy of DPP-4 inhibitors, GLP-1 analogues, and SGLT2 inhibitors as add-ons to metformin monotherapy in T2DM patients: a model-based meta-analysis","volume":"85","author":"Inoue","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.diabet.2020.01.002_bib1195","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.diabres.2014.06.006","article-title":"Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: systematic review and meta-analyses","volume":"105","author":"Zhang","year":"2014","journal-title":"Diab Res Clin Pract"},{"key":"10.1016\/j.diabet.2020.01.002_bib1200","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11886-019-1165-1","article-title":"Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure","volume":"21","author":"Scheen","year":"2019","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.diabet.2020.01.002_bib1205","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.diabet.2018.09.005","article-title":"Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: potential contribution for diabetic complications and cardiovascular disease","volume":"44","author":"Bonnet","year":"2018","journal-title":"Diab Metab"},{"key":"10.1016\/j.diabet.2020.01.002_bib1210","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.diabet.2019.01.008","article-title":"Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: a common comorbidity associated with severe complications","volume":"45","author":"Scheen","year":"2019","journal-title":"Diab Metab"},{"key":"10.1016\/j.diabet.2020.01.002_bib1215","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.diabres.2018.10.023","article-title":"Why not adding a glucose-lowering agent with proven cardioprotection in high-risk patients with type 2 diabetes at HbA1c target on metformin?","volume":"147","author":"Scheen","year":"2019","journal-title":"Diab Res Clin Pract"},{"key":"10.1016\/j.diabet.2020.01.002_bib1220","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.diabet.2016.09.005","article-title":"Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: meta-analysis of placebo-controlled randomized clinical trials","volume":"43","author":"Rehman","year":"2017","journal-title":"Diab Metab"},{"key":"10.1016\/j.diabet.2020.01.002_bib1225","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.diabet.2018.10.003","article-title":"Effects of glucose-lowering agents on renal surrogate endpoints and hard clinical outcomes in patients with type 2 diabetes","volume":"45","author":"Scheen","year":"2019","journal-title":"Diab Metab"},{"key":"10.1016\/j.diabet.2020.01.002_bib1230","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.diabet.2017.04.004","article-title":"Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes","volume":"43","author":"Bonnet","year":"2017","journal-title":"Diab Metab"},{"key":"10.1016\/j.diabet.2020.01.002_bib1235","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabet.2020.01.002_bib1240","article-title":"Challenging 2019 ESC guidelines for the management of type 2 diabetes","author":"Scheen","year":"2019","journal-title":"Diab Metab"},{"key":"10.1016\/j.diabet.2020.01.002_bib9240","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00125-019-05039-w","article-title":"2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"63","author":"Buse","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2020.01.002_bib1245","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/14740338.2018.1444027","article-title":"The safety of gliptins: updated data in 2018","volume":"17","author":"Scheen","year":"2018","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.diabet.2020.01.002_bib1250","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/14740338.2019.1602116","article-title":"An update on the safety of SGLT2 inhibitors","volume":"18","author":"Scheen","year":"2019","journal-title":"Expert Opin Drug Safety"}],"container-title":["Diabetes & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363620300173?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363620300173?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:56:26Z","timestamp":1761130586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363620300173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":126,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S1262363620300173"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2020.01.002","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2020.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}